Daiwa Securities Group Inc. - INTRA CELLULAR THERAPIES INC ownership

INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 135 filers reported holding INTRA CELLULAR THERAPIES INC in Q3 2019. The put-call ratio across all filers is 2.11 and the average weighting 0.0%.

Quarter-by-quarter ownership
Daiwa Securities Group Inc. ownership history of INTRA CELLULAR THERAPIES INC
ValueSharesWeighting
Q3 2023$18
-18.2%
3450.0%0.00%
Q2 2023$22
+4.8%
345
-9.4%
0.00%
Q1 2023$21
+5.0%
3810.0%0.00%
Q4 2022$20
-99.9%
381
+8.2%
0.00%
Q3 2022$16,000
-20.0%
3520.0%0.00%
Q2 2022$20,000
+17.6%
352
+27.1%
0.00%
Q1 2022$17,000
+41.7%
277
+16.4%
0.00%
Q4 2021$12,000
+20.0%
238
-14.7%
0.00%
Q3 2021$10,000
+66.7%
279
+84.8%
0.00%
Q2 2021$6,000
+20.0%
1510.0%0.00%
Q1 2021$5,0000.0%1510.0%0.00%
Q4 2020$5,000
-44.4%
151
-58.5%
0.00%
Q3 2020$9,000
+50.0%
3640.0%0.00%
Q2 2020$6,0000.0%3640.0%0.00%
Q1 2020$6,000
-40.0%
364
+20.5%
0.00%
Q4 2019$10,000
+400.0%
3020.0%0.00%
Q3 2019$2,000
-50.0%
3020.0%0.00%
Q2 2019$4,0000.0%3020.0%0.00%
Q1 2019$4,000
+33.3%
3020.0%0.00%
Q4 2018$3,000
-57.1%
3020.0%0.00%
Q3 2018$7,000
+40.0%
3020.0%0.00%
Q2 2018$5,000
-16.7%
3020.0%0.00%
Q1 2018$6,0003020.00%
Other shareholders
INTRA CELLULAR THERAPIES INC shareholders Q3 2019
NameSharesValueWeighting ↓
TANG CAPITAL MANAGEMENT LLC 700,000$42,833,0008.57%
SILVERARC CAPITAL MANAGEMENT, LLC 308,819$18,897,0007.82%
Vahanian & Associates Financial Planning Inc. 45,533$2,786,0006.44%
DCF Advisers, LLC 238,500$14,594,0006.39%
INTERNATIONAL BIOTECHNOLOGY TRUST PLC 50,956$20,930,0004.72%
SUVRETTA CAPITAL MANAGEMENT, LLC 1,531,923$93,738,0002.86%
Nicholas Investment Partners, LP 562,373$34,412,0002.45%
Bellevue Group AG 3,429,619$209,859,0002.44%
WASATCH ADVISORS LP 7,477,868$457,571,0002.25%
Quantum Private Wealth, LLC 73,772$4,514,0001.95%
View complete list of INTRA CELLULAR THERAPIES INC shareholders